LifeTech Scientific's (HKG:1302) Five-year Earnings Growth Trails the Respectable Shareholder Returns
LifeTech Scientific's (HKG:1302) Five-year Earnings Growth Trails the Respectable Shareholder Returns
While LifeTech Scientific Corporation (HKG:1302) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 18% in the last quarter. But that doesn't change the fact that the returns over the last five years have been pleasing. After all, the share price is up a market-beating 45% in that time.
而当生命科技科技公司(HKG:1302)股东可能普遍满意,该股最近表现不是特别好,股价在上个季度下跌了18%。但这并不能改变过去五年回报一直令人满意的事实。毕竟,在这段时间里,该公司股价上涨了45%,涨幅超过了市场。
The past week has proven to be lucrative for LifeTech Scientific investors, so let's see if fundamentals drove the company's five-year performance.
过去一周对LifeTech Science的投资者来说被证明是有利可图的,所以让我们看看基本面因素是否推动了该公司五年的业绩。
See our latest analysis for LifeTech Scientific
查看我们对LifeTech Science的最新分析
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
用巴菲特的话说,“船只将在世界各地航行,但平坦的地球协会将蓬勃发展。市场上的价格和价值之间将继续存在巨大的差异……”考察市场情绪如何随时间变化的一种方法是观察一家公司的股价和每股收益(EPS)之间的相互作用。
Over half a decade, LifeTech Scientific managed to grow its earnings per share at 16% a year. The EPS growth is more impressive than the yearly share price gain of 8% over the same period. So one could conclude that the broader market has become more cautious towards the stock.
在过去的五年里,LifeTech Science设法以每年16%的速度增长每股收益。每股收益的增长比同期8%的年股价涨幅更令人印象深刻。因此,人们可以得出结论,更广泛的市场对该股已变得更加谨慎。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
您可以在下面看到EPS是如何随着时间的推移而变化的(通过单击图像来了解确切的值)。
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在买卖股票之前,我们总是建议仔细研究一下历史增长趋势,可以在这里找到。
A Different Perspective
不同的视角
Investors in LifeTech Scientific had a tough year, with a total loss of 7.2%, against a market gain of about 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Is LifeTech Scientific cheap compared to other companies? These 3 valuation measures might help you decide.
LifeTech Science的投资者经历了艰难的一年,总亏损7.2%,而市场收益约为12%。然而,请记住,即使是最好的股票,在12个月的时间里,有时也会表现逊于市场。较长期的投资者不会如此沮丧,因为他们在五年内每年会获得8%的收益。如果基本面数据继续显示长期可持续增长,当前的抛售可能是一个值得考虑的机会。LifeTech Science与其他公司相比便宜吗?这3个估值指标可能会帮助你做出决定。
Of course LifeTech Scientific may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然了LifeTech Science可能不是最值得买入的股票。所以你可能想看看这个免费成长型股票的集合。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。